secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001628280-22-020850
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

COMPASS Pathways reports Q2 net loss of $21.0M, appoints Kabir Nath as CEO
--------------------------------------------------------------------------

- Net loss for Q2 2022 was $21.0M ($0.50 loss per share) vs $17.5M ($0.44) in Q2 2021.
- Cash and cash equivalents of $207.2M at June 30, 2022, down from $273.2M at Dec 31, 2021.
- Kabir Nath appointed CEO; George Goldsmith remains Executive Chairman through Dec 2022.
- Phase 3 protocols for COMP360 in TRD submitted to FDA, under review; Phase 3 start expected Q4 2022.
- Phase 2 study of COMP360 in anorexia nervosa launched across four research sites in the UK and US.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000162828022020850/0001628280-22-020850-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000162828022020850/cmps-20220804.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-020850

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer